CANTON, Mass., Nov. 1 /PRNewswire-FirstCall/ -- Avitar (OTC Bulletin Board: - ) will present at the 4th Annual PIPEs Conference 2006 being held in New York City at The Waldorf-Astoria Hotel on November 7 and 8, 2006. Avitar will present on Tuesday, November 7th at both 9:30 AM and 10:00 AM and at 9:00 AM EST, on Wednesday, November 8th.
Pete Phildius, Chief Executive Officer of Avitar, and Jay Leatherman, Chief Financial Officer, will discuss both the corporate and financial highlights of the Company.
Conference officials estimate this year's audience to be in excess of 1,000 people, consisting primarily of investors, investment bankers, attorneys, company executives and industry analysts active in the small cap equity market. The conference includes CLE-accredited workshops, roundtables, and presentations from leading industry professionals. Information about the event can be found at http://www.thepipesconference.com.
About Avitar, Inc.
Avitar, Inc. develops, manufactures and markets innovative and proprietary products. Its field includes the oral fluid diagnostic market, the disease and clinical testing market, and customized polyurethane applications used in the wound dressing industry. Avitar manufactures ORALscreen® the world's first non-invasive, rapid, on-site, fluid-based oral screening test for drugs-of-abuse, as well as HYDRASORB®, an absorbent topical dressing for moderate to heavy exudating wounds. Avitar is also developing diagnostic strategies for disease and clinical testing in the estimated $25 billion in-vitro diagnostics market. Conditions targeted include influenza, diabetes, and pregnancy. For more information, visit Avitar's Web site at https://avitarinc.com.
Forward Looking Statements
This release contains forward looking statements that are subject to risks and uncertainties including the development and marketing of new applications and other risks that are detailed from time to time in the Company's filings with the Securities and Exchange Commission. In view of such risks and uncertainties, the Company's actual results could differ materially from those anticipated in such forward looking statements.
Jay C. Leatherman
The Investor Relations Group